Yamagishi Makoto
Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo.
Rinsho Ketsueki. 2022;63(9):1157-1166. doi: 10.11406/rinketsu.63.1157.
Malignant lymphomas are a group of diseases in which epigenomic abnormalities are fundamental to the pathogenesis and pathophysiology and are characterized by a high frequency of abnormalities in DNA methylation regulators and histone modifiers. These epigenomic abnormalities directly amplify malignant clones. They also originated from a cell lineage differentiated from hematopoietic stem cells through epigenomic changes. These characteristics are associated with their high affinity for epigenomic therapies. Hematology has been a leader in the basic, clinical, and drug discovery areas of disease epigenetics. However, the epigenomic regulation is generally recognized as a complex system, and gaps are observed between basic and clinical studies. To overview the status and importance of "epigenomic abnormalities in malignant lymphoma," this review first summarizes the concept and essential importance of the epigenome and then outlines the current status and future perspective of epigenomic abnormalities in malignant lymphomas.
恶性淋巴瘤是一组疾病，其中表观基因组异常是发病机制和病理生理学的基础，其特征是DNA甲基化调节因子和组蛋白修饰因子异常的频率很高。这些表观基因组异常直接扩增恶性克隆。它们还通过表观基因组变化起源于从造血干细胞分化而来的细胞谱系。这些特征与它们对表观基因组疗法的高亲和力相关。血液学在疾病表观遗传学的基础、临床和药物发现领域一直处于领先地位。然而，表观基因组调控通常被认为是一个复杂的系统，基础研究和临床研究之间存在差距。为了概述“恶性淋巴瘤中的表观基因组异常”的现状和重要性，本综述首先总结了表观基因组的概念和重要意义，然后概述了恶性淋巴瘤表观基因组异常的现状和未来前景。
